SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice

In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated beneficial renoprotective effects, which culminated in the recent approval of their use for patients with chronic kidney disease (CKD), following a similar path to one they had already crossed due to their cardiop...

Descripción completa

Detalles Bibliográficos
Autores principales: Skrabic, Roko, Kumric, Marko, Vrdoljak, Josip, Rusic, Doris, Skrabic, Ivna, Vilovic, Marino, Martinovic, Dinko, Duplancic, Vid, Ticinovic Kurir, Tina, Bozic, Josko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598622/
https://www.ncbi.nlm.nih.gov/pubmed/36289720
http://dx.doi.org/10.3390/biomedicines10102458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598622/
https://www.ncbi.nlm.nih.gov/pubmed/36289720
http://dx.doi.org/10.3390/biomedicines10102458

Ejemplares similares